Core Viewpoint - Allarity Therapeutics has received formal acceptance of its patent application for the Drug Response Predictor (DRP) companion diagnostic specific to stenoparib from IP Australia, marking a significant step in its global strategy for intellectual property protection and commercialization of its proprietary technology [1][2][3]. Company Overview - Allarity Therapeutics, Inc. is a Phase 2 clinical-stage pharmaceutical company focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, as a personalized cancer treatment using its proprietary DRP technology [1][6]. - The company is headquartered in the U.S. and has a research facility in Denmark, aiming to address significant unmet medical needs in cancer treatment [6]. Patent and Intellectual Property - The accepted patent covers 40 claims and is a crucial part of Allarity's strategy to protect its DRP platform internationally, with the patent expected to be granted within 20 working days if unopposed [2][3]. - Allarity has previously secured a European patent for the stenoparib DRP and holds 18 granted patents for drug-specific DRPs, including eight in the U.S. [3]. Drug and Technology Details - Stenoparib is an orally available small-molecule inhibitor targeting PARP1/2 and tankyrase 1/2, with potential applications in various cancer types, particularly ovarian cancer [4]. - The DRP technology is designed to select patients likely to benefit from specific drugs based on gene expression signatures, enhancing therapeutic benefit rates [5]. Future Prospects - The acceptance of the Australian patent is seen as a vital achievement in securing international IP protection while advancing stenoparib through Phase 2 trials towards U.S. regulatory approval [3].

TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today announced that the second patient has been dosed in its new Phase 2 clinical trial protocol evaluating stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. Commenting on the development, Thomas Jensen ...

Core Viewpoint - Allarity Therapeutics has appointed Jesper Høiland to its Board of Directors, replacing Joseph Vazzano, as the company prepares for the next phases of clinical development and potential commercialization of its cancer treatment, stenoparib [1][4]. Group 1: Leadership Changes - Jesper Høiland has been a strategic consultant for Allarity since October 2024 and brings over 30 years of experience in global pharmaceutical commercialization [2][3]. - Joseph Vazzano will resign from the Board effective June 30, 2025, after contributing to Allarity's development for two years [1][4]. Group 2: Company Overview - Allarity Therapeutics is a Phase 2 clinical-stage pharmaceutical company focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, as a personalized cancer treatment [1][7]. - The company utilizes its proprietary Drug Response Predictor (DRP) technology to select patients who may benefit most from stenoparib [6][8]. Group 3: Product Information - Stenoparib is an orally available small-molecule inhibitor targeting PARP1/2 and tankyrase 1/2, with potential applications in various cancers, including ovarian cancer [5]. - Allarity holds exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [5]. Group 4: Strategic Importance - The appointment of Jesper Høiland is seen as a strategic move to enhance Allarity's governance and operational focus during a critical time in the company's development [4]. - Høiland's experience in preparing for the commercialization phase of investigational drugs is expected to be valuable as Allarity advances its clinical development [4].

The Indiana Biosciences Research Institute (IBRI) is a leading translational research institute that accelerates innovation by bridging academic and industry science through collaboration. Its team of scientists is focused on solving high-impact biomedical challenges in areas such as cancer, diabetes, Alzheimer's disease, and pediatric rare diseases, while also providing molecular innovation platforms and enabling technologies to drive the development of novel therapies. For more information, visit indianab ...

TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the treatment of advanced, platinum-resistant or platinum-ineligible ovarian cancer. The newly launched protocol will accelerate the clinical d ...

- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months- Initiated utilization of share repurchase program- Cash and restricted cash balance of approximately $27 million at end of Q1 2025, reinforcing financial stability TARPON SPRINGS, Fla., May 9, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing sten ...

TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology today announced the presentation of a poster containing data on a new DRP for the monoclonal antibody drug daratumumab. The post ...

Core Insights - Allarity Therapeutics has made significant advancements in the development of stenoparib, a dual PARP/WNT pathway inhibitor, particularly for advanced ovarian cancer treatment [1][2] - The company has undergone a strategic realignment to focus exclusively on stenoparib, discontinuing other clinical programs, which has accelerated progress in its clinical trials [2][3] - Financially, Allarity has strengthened its position, with a cash balance of approximately $25 million at the end of Q1 2025, providing a runway into 2027 for ongoing clinical activities [2][9] Clinical and Drug Development Progress - In 2024, Allarity executed a strategic realignment to focus solely on stenoparib, leading to accelerated progress in its clinical program [2] - The company reported a cash and cash receivable balance of $20.9 million as of December 31, 2024, which is expected to fund operations into 2027 [2][9] - Stenoparib has shown durable clinical benefits in heavily pre-treated ovarian cancer patients, with some patients remaining on treatment for over 17 months [3][4] Leadership Changes - Thomas Jensen has been appointed as the permanent CEO, transitioning from interim status, with a focus on advancing Allarity's strategic and clinical goals [8] - Key appointments include Jeremy Graff as President and Chief Development Officer, and Jose Iglesias as Consultant Chief Medical Officer, both bringing extensive oncology experience [8] Financial Strengthening and Corporate Development - The company reported a net loss of $24.5 million for 2024, an increase from $11.9 million in 2023, largely due to a non-cash impairment charge and costs related to an SEC investigation [10][21] - Allarity has implemented cost-reduction initiatives to strengthen financial sustainability while prioritizing stenoparib's advancement [8] - A $5 million share repurchase program has been authorized to reinforce long-term shareholder value [8] Regulatory and Compliance Resolutions - Allarity has resolved outstanding regulatory matters with the SEC related to past disclosures, allowing the company to focus on clinical and corporate progress [8] - The company regained compliance with Nasdaq listing requirements following a successful hearing [8]